propranolol has been researched along with Liver Dysfunction in 31 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol has been shown to be effective in both primary and secondary treatment of variceal haemorrhage; most primary prevention trials have only included patients with large oesophageal varices." | 5.07 | Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. ( Bouchier, IA; Davies, JM; Elliot, R; Hayes, PC; Hislop, WS; Mills, PR; Plevris, JN, 1994) |
| "0 years, 34 boys) with CLD who needed liver biopsy but could not be done due to hypersplenism-related thrombocytopenia (platelets <100,000/mm(3) and/or total leukocyte counts <4,000/mm(3) with splenomegaly) were recruited and given a 4-week trial of long-acting propranolol (1." | 3.81 | β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children. ( Agarwal, J; Baijal, SS; Kumar, S; Poddar, U; Shava, U; Srivastava, A; Yachha, SK, 2015) |
| " This study shows that long-term treatment with propranolol is safe in patients with chronic liver disease but further studies are required to define whether or not patients will benefit." | 2.66 | Propranolol in chronic liver disease: a controlled trial of its effect and safety over twelve months. ( Bouchier, IA; Crichton, S; Hayes, PC; Shepherd, AN, 1987) |
| "Propranolol treatment was associated with a significant rise in body weight after 9 months and significant rises in skinfold thickness and body fat after 12 months." | 2.65 | Influence of propranolol on weight and salt and water homoeostasis in chronic liver disease. ( Bouchier, IA; Hayes, PC; Stewart, WW, 1984) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| " We conclude that, although propranolol may have some influence on drug handling acutely, chronic administration does not interfere with hepatic drug metabolism or renal drug clearance." | 1.28 | Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease. ( Bouchier, IA; Hayes, PC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (64.52) | 18.7374 |
| 1990's | 5 (16.13) | 18.2507 |
| 2000's | 1 (3.23) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Panda, SK | 1 |
| Nikhila, GP | 1 |
| Kavya, PS | 1 |
| Bustinduy, AL | 1 |
| Luzinda, K | 1 |
| Mpoya, S | 1 |
| Gothard, P | 1 |
| Stone, N | 1 |
| Wright, S | 1 |
| Stothard, JR | 1 |
| Poddar, U | 1 |
| Shava, U | 1 |
| Yachha, SK | 1 |
| Agarwal, J | 1 |
| Kumar, S | 1 |
| Baijal, SS | 1 |
| Srivastava, A | 1 |
| Ozden, I | 1 |
| Imura, S | 1 |
| Erlinger, S | 1 |
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Malè, PJ | 1 |
| Hayes, PC | 4 |
| Stewart, WW | 1 |
| Bouchier, IA | 4 |
| Abadie, E | 1 |
| Lombrail, P | 1 |
| Vesell, ES | 1 |
| Kostrzewska, E | 1 |
| Jacobs, MB | 1 |
| Eisenburg, J | 1 |
| Plevris, JN | 1 |
| Elliot, R | 1 |
| Mills, PR | 1 |
| Hislop, WS | 1 |
| Davies, JM | 1 |
| Melissant, CF | 1 |
| Smith, SJ | 1 |
| Kazzaz, BA | 1 |
| Demedts, M | 1 |
| Paumgartner, G | 1 |
| Wilkinson, GR | 1 |
| Branch, RA | 3 |
| Shand, DG | 1 |
| James, J | 1 |
| Read, AE | 2 |
| Calès, P | 1 |
| Ochi, Y | 1 |
| Yumori, Y | 1 |
| Morioka, A | 1 |
| Miura, K | 1 |
| Tsukamoto, I | 1 |
| Kojo, S | 1 |
| Isozaki, S | 1 |
| Hartleb, M | 1 |
| Markiewicz, A | 1 |
| Rudzki, K | 1 |
| Nowak, S | 1 |
| Bołdys, H | 1 |
| Kacperek, T | 1 |
| Crichton, S | 1 |
| Shepherd, AN | 1 |
| Srugo, I | 1 |
| Said, E | 1 |
| Korman, S | 1 |
| Jaffe, M | 1 |
| Kunze, KD | 1 |
| Porst, H | 1 |
| Tschöpel, L | 1 |
| James, JA | 1 |
| Kessler, KM | 1 |
| Prodanov, A | 1 |
| Popnikolov, S | 1 |
| Talakov, A | 1 |
| Slaviiska, V | 1 |
| Levy, RH | 1 |
| Smith, GH | 1 |
5 reviews available for propranolol and Liver Dysfunction
| Article | Year |
|---|---|
Noninvasive assessment in vivo of hepatic drug metabolism in health and disease.
Topics: Adult; Aminopyrine; Animals; Antipyrine; Breath Tests; Humans; Liver; Liver Cirrhosis; Liver Disease | 1984 |
[Typical risks in the treatment of acute and chronic liver diseases].
Topics: Androgens; Ascites; Cholestyramine Resin; Cimetidine; Disseminated Intravascular Coagulation; Diuret | 1982 |
The application of clearance concepts to propranolol disposition in man.
Topics: Aging; Half-Life; Humans; Liver; Liver Diseases; Models, Biological; Propranolol; Smoking; Time Fact | 1979 |
Propranolol disposition in chronic liver disease: a physiological approach.
Topics: Administration, Oral; Blood Proteins; Chronic Disease; Half-Life; Humans; Kinetics; Liver; Liver Cir | 1976 |
Individualization of dosage of antiarrhythmic drugs.
Topics: Dose-Response Relationship, Drug; Drug Interactions; Electrocardiography; Heart Diseases; Humans; Ki | 1974 |
3 trials available for propranolol and Liver Dysfunction
| Article | Year |
|---|---|
Influence of propranolol on weight and salt and water homoeostasis in chronic liver disease.
Topics: Adipose Tissue; Body Weight; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; | 1984 |
Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease.
Topics: Adult; Aged; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Esophageal and Gastric V | 1994 |
Propranolol in chronic liver disease: a controlled trial of its effect and safety over twelve months.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Liver D | 1987 |
23 other studies available for propranolol and Liver Dysfunction
| Article | Year |
|---|---|
Propranolol in Congenital Hepatic Arteriovenous Malformation.
Topics: Arteriovenous Malformations; Hemangioma; Humans; Liver Diseases; Propranolol | 2023 |
Endomyocardial fibrosis (EMF) in a Ugandan child with advanced hepatosplenic schistosomiasis: coincidence or connection?
Topics: Animals; Anthelmintics; Child; Endomyocardial Fibrosis; Feces; Humans; Liver Diseases; Male; Praziqu | 2014 |
β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Biopsy; Child; Child, Preschool; Female; Humans; Hypersplen | 2015 |
Somatostatin and propranolol for the treatment of small-for-size syndrome after liver transplantation.
Topics: Cardiovascular Agents; Humans; Liver Diseases; Liver Transplantation; Living Donors; Organ Size; Pro | 2008 |
Sir James Black (1924-2010), β-blockers and liver disease.
Topics: Adrenergic beta-Antagonists; Biomedical Research; Drug Industry; Heart Diseases; Histamine H2 Antago | 2010 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
[Beta-blockers in gastroenterology and hepatology].
Topics: Adrenergic beta-Antagonists; Cimetidine; Drug Combinations; Gastrointestinal Diseases; Humans; Liver | 1984 |
Propranolol and salt and water homoeostasis in chronic liver disease.
Topics: Body Water; Chronic Disease; Humans; Liver Diseases; Propranolol; Sodium | 1984 |
[Treatment of acute hepatic porphyria].
Topics: Acute Disease; Adolescent; Adult; Combined Modality Therapy; Dietary Carbohydrates; Dietary Proteins | 1984 |
Hepatic infarction related to oral contraceptive use.
Topics: Adult; Aortography; Chemical and Drug Induced Liver Injury; Contraceptives, Oral; Female; Hepatic Ar | 1984 |
Bleeding varices due to portal hypertension in sarcoidosis. Favorable effect of propranolol and prednisone.
Topics: Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hype | 1993 |
[Drug metabolism in liver diseases].
Topics: Antipyrine; Biological Availability; Biotransformation; Diazepam; Humans; Liver; Liver Diseases; Pha | 1979 |
A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.
Topics: Adult; Aged; Chronic Disease; Female; Glomerular Filtration Rate; Hepatitis; Humans; Liver Cirrhosis | 1976 |
Propranolol in the prevention of ascites.
Topics: Ascites; Follow-Up Studies; Humans; Liver Diseases; Propranolol | 1991 |
Effect of alpha-blockade on liver regeneration after carbon tetrachloride intoxication in the rat.
Topics: Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; | 1990 |
[Therapeutic drug monitoring of propranolol hydrochloride].
Topics: Administration, Oral; Aged; Aged, 80 and over; Biological Availability; Chromatography, Gas; Chromat | 1990 |
Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Chronic Disease; Drug Administration Schedule; Female; Human | 1989 |
[Clinical variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. II. Effect of propranolol].
Topics: Adult; Antipyrine; Circadian Rhythm; Contrast Media; Female; Humans; Imino Acids; Liver; Liver Disea | 1987 |
Acute intermittent porphyria--an unusual cause of "surgical" abdomen. Response to propranolol therapy.
Topics: Abdomen, Acute; Adolescent; Humans; Liver Diseases; Male; Porphyrias; Propranolol | 1987 |
[Morphology and pathogenesis of liver injury produced by dihydralazine , propranolol and ketophenylbutazone].
Topics: Chemical and Drug Induced Liver Injury; Dihydralazine; Humans; Hydralazine; Immunity, Cellular; Live | 1985 |
Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
Topics: Administration, Oral; Antipyrine; Bilirubin; Chronic Disease; Humans; Indocyanine Green; Liver; Live | 1974 |
[Liver disorders in Inderal therapy].
Topics: Aged; Arrhythmias, Cardiac; Autopsy; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; | 1972 |
Dosage regimens of antiarrhythmics. II. Applications.
Topics: Anti-Arrhythmia Agents; Heart Failure; Humans; Injections, Intravenous; Kidney Diseases; Lidocaine; | 1973 |